blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4000630

EP4000630 - INCRETIN FOR ELEVATED INTRACRANIAL PRESSURE TREATMENT [Right-click to bookmark this link]
Former [2022/21]ELEVATED INTRACRANIAL PRESSURE TREATMENT
[2023/28]
StatusNo opposition filed within time limit
Status updated on  18.10.2024
Database last updated on 31.03.2026
FormerThe patent has been granted
Status updated on  10.11.2023
FormerGrant of patent is intended
Status updated on  06.07.2023
FormerRequest for examination was made
Status updated on  18.11.2022
FormerThe application has been published
Status updated on  22.04.2022
Most recent event   Tooltip13.03.2026Lapse of the patent in a contracting state
New state(s): HU		published on 15.04.2026 [2026/16]
Applicant(s)For all designated states
Invex Therapeutics Ltd
Level 1
38 Rowland St.
Subiaco, Perth WA 6008 / AU
[2022/21]
Inventor(s)01 / SINCLAIR, Alex
Birmingham, B15 2TT / GB
 [2022/21]
Representative(s)HGF
HGF Limited
4th Floor, 1 City Square
Leeds LS1 2ES / GB
[N/P]
Former [2022/21]HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
Application number, filing date21194436.825.08.2015
[2022/21]
Priority number, dateGB2014001559803.09.2014         Original published format: GB 201415598
[2022/21]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4000630
Date:25.05.2022
Language:EN
[2022/21]
Type: B1 Patent specification 
No.:EP4000630
Date:13.12.2023
Language:EN
[2023/50]
Search report(s)(Supplementary) European search report - dispatched on:EP30.03.2022
ClassificationIPC:A61K38/26, C07K14/605, A61P25/00, A61P43/00, C07K14/575
[2022/21]
CPC:
A61K38/26 (EP,US); A61P25/00 (EP,US); A61P43/00 (EP,US);
C07K14/57563 (EP,US); C07K14/605 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/51]
Former [2022/21]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:INCRETIN ZUR BEHANDLUNG VON ERHÖHTEM INTRAKRANIALEM DRUCK[2023/28]
English:INCRETIN FOR ELEVATED INTRACRANIAL PRESSURE TREATMENT[2023/28]
French:INCRETIN POUR TRAITEMENT DE LA PRESSION INTRACRÂNIENNE ÉLEVÉE[2023/28]
Former [2022/21]BEHANDLUNG VON ERHÖHTEM INTRAKRANIALEM DRUCK
Former [2022/21]ELEVATED INTRACRANIAL PRESSURE TREATMENT
Former [2022/21]TRAITEMENT DE LA PRESSION INTRACRÂNIENNE ÉLEVÉE
Examination procedure16.11.2022Amendment by applicant (claims and/or description)
16.11.2022Examination requested  [2022/51]
16.11.2022Date on which the examining division has become responsible
07.07.2023Communication of intention to grant the patent
03.11.2023Fee for grant paid
03.11.2023Fee for publishing/printing paid
03.11.2023Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP15757548.1  / EP3188747
Opposition(s)16.09.2024No opposition filed within time limit [2024/47]
Fees paidRenewal fee
01.09.2021Renewal fee patent year 03
01.09.2021Renewal fee patent year 04
01.09.2021Renewal fee patent year 05
01.09.2021Renewal fee patent year 06
01.09.2021Renewal fee patent year 07
07.07.2022Renewal fee patent year 08
13.07.2023Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY25.08.2015
HU25.08.2015
AT13.12.2023
CZ13.12.2023
DK13.12.2023
EE13.12.2023
FI13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
MC13.12.2023
NL13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SE13.12.2023
SI13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
IE25.08.2024
LU25.08.2024
BE31.08.2024
CH31.08.2024
[2026/16]
Former [2026/10]CY25.08.2015
AT13.12.2023
CZ13.12.2023
DK13.12.2023
EE13.12.2023
FI13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
MC13.12.2023
NL13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SE13.12.2023
SI13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
IE25.08.2024
LU25.08.2024
BE31.08.2024
CH31.08.2024
Former [2025/45]AT13.12.2023
CZ13.12.2023
DK13.12.2023
EE13.12.2023
FI13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
MC13.12.2023
NL13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SE13.12.2023
SI13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
IE25.08.2024
LU25.08.2024
BE31.08.2024
CH31.08.2024
Former [2025/36]AT13.12.2023
CZ13.12.2023
DK13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
MC13.12.2023
NL13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SE13.12.2023
SI13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
IE25.08.2024
LU25.08.2024
BE31.08.2024
CH31.08.2024
Former [2025/34]AT13.12.2023
CZ13.12.2023
DK13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
MC13.12.2023
NL13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SE13.12.2023
SI13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
LU25.08.2024
BE31.08.2024
CH31.08.2024
Former [2025/22]AT13.12.2023
CZ13.12.2023
DK13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
MC13.12.2023
NL13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SE13.12.2023
SI13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
LU25.08.2024
CH31.08.2024
Former [2025/21]AT13.12.2023
CZ13.12.2023
DK13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
NL13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SE13.12.2023
SI13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
LU25.08.2024
Former [2024/49]AT13.12.2023
CZ13.12.2023
DK13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
NL13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SE13.12.2023
SI13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
Former [2024/47]AT13.12.2023
CZ13.12.2023
DK13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
NL13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SE13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
Former [2024/36]AT13.12.2023
CZ13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
NL13.12.2023
PL13.12.2023
RO13.12.2023
RS13.12.2023
SE13.12.2023
SK13.12.2023
SM13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
PT15.04.2024
Former [2024/35]AT13.12.2023
CZ13.12.2023
EE13.12.2023
HR13.12.2023
LT13.12.2023
LV13.12.2023
NL13.12.2023
RO13.12.2023
RS13.12.2023
SE13.12.2023
SM13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/33]HR13.12.2023
LT13.12.2023
LV13.12.2023
NL13.12.2023
RS13.12.2023
SE13.12.2023
SM13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/32]HR13.12.2023
LT13.12.2023
LV13.12.2023
NL13.12.2023
RS13.12.2023
SE13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
IS13.04.2024
Former [2024/27]HR13.12.2023
LT13.12.2023
LV13.12.2023
NL13.12.2023
RS13.12.2023
SE13.12.2023
BG13.03.2024
NO13.03.2024
GR14.03.2024
Former [2024/21]LT13.12.2023
BG13.03.2024
GR14.03.2024
Former [2024/20]GR14.03.2024
Documents cited:Search[A] WO2007027225  (ARENA PHARM INC et al.)
 [A]   KATHARINE EAKIN ET AL: "Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats", PLOS ONE, vol. 8, no. 12, E82016, 2 December 2013 (2013-12-02), pages 1 - 8, XP055225068, DOI: 10.1371/journal.pone.0082016

DOI:   http://dx.doi.org/10.1371/journal.pone.0082016
 [A]   JACK HOU ET AL: "Liraglutide, a long-acting GLP-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage", JOURNAL OF CEREBRAL BLOOD FLOW & METABOLISM, vol. 32, no. 12, 12 September 2012 (2012-09-12), US, pages 2201 - 2210, XP055225067, ISSN: 0271-678X, DOI: 10.1038/jcbfm.2012.133

DOI:   http://dx.doi.org/10.1038/jcbfm.2012.133
 [A]   DAVID TWEEDIE ET AL: "Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice", EXPERIMENTAL NEUROLOGY, vol. 239, 1 January 2013 (2013-01-01), US, pages 170 - 182, XP055225069, ISSN: 0014-4886, DOI: 10.1016/j.expneurol.2012.10.001

DOI:   http://dx.doi.org/10.1016/j.expneurol.2012.10.001
 [AP]   HAKON JAKOB ET AL: "Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury.", PLOS ONE, vol. 10, no. 3, E0120074, 2015, pages 1 - 17, XP002749961, ISSN: 1932-6203

DOI:   http://dx.doi.org/10.1371/journal.pone.0120074
 [T]   HANNAH BOTFIELD, MARIA ULDALL, JAMES MITCHELL, ANA MARIA GONZALEZ, RIGMOR JENSEN, ALEXANDRA SINCLAIR: "GLP-1 reduces cerebrospinal fluid secretion and intracranial pressure: a novel treatment for idiopathic intracranial hypertension?", 30 October 2015 (2015-10-30), XP002749962, Retrieved from the Internet [retrieved on 20151030]

DOI:   http://dx.doi.org/10.1530/endoabs.38.FP4
 [A]   FORSTER N ET AL: "Managing elevated intracranial pressure", CURRENT OPINION IN ANAESTHESIOLOGY, vol. 17, no. 5, 1 October 2004 (2004-10-01), LIPPINCOTT WILLIAMS & WILKINS, US, pages 371 - 376, XP009187003, ISSN: 0952-7907, DOI: 10.1097/00001503-200410000-00004

DOI:   http://dx.doi.org/10.1097/00001503-200410000-00004
by applicantUS2008015144
 US2011274747
 WO9907404
 WO9925727
 WO9925728
 WO9940788
 WO0041546
 WO0041548
 WO2009035540
 US6593295
 US6569832
 US6528486
 US6514500
 US6458924
 US6451987
 US6451974
 US6268343
 WO2007027225
 US6303661
 US6812350
 US6803357
 US6710040
 US6617340
 US6699871
 US6573287
 US6432969
 US6395767
 US6242422
 US6166063
 WO2004103993
 WO2004103276
 WO2004099134
 WO2004087053
 WO2004076434
 WO2004076433
 WO2004069162
 WO2004064778
 WO2004071454
 WO2004067509
 WO2004058266
 WO2004052850
 WO2004050022
 WO2004050658
 WO2004032836
 WO2004046106
 WO2004043940
 WO2004041795
 WO2004037169
 WO2004037181
 WO03101958
 WO2004014860
 WO2004007468
 WO2004004661
 WO03082817
 WO03072528
 WO03057666
 WO03057144
 WO03040174
 WO03037327
 WO03035067
 WO03035057
 WO03022871
 WO03015775
 WO03004498
 WO03002530
 WO03002596
 WO03002595
 WO03002593
 WO03002553
 WO03002531
 WO03000181
 WO03000180
 WO03000250
 WO02083109
 WO02083128
 WO02076450
 WO02051836
 WO0234900
 WO0196295
 WO0181337
 WO0181304
 WO0168603
 WO0134594
 WO0023421
 WO9967278
 WO9961431
 WO9819998
 WO9740832
   ENG, J. ET AL., J. BIOL. CHEM., vol. 265, 1990, pages 20259 - 62
   ENG, J. ET AL., J. BIOL. CHEM., vol. 267, 1992, pages 7402 - 05
   VILLHAUER ET AL., J MED CHEM, vol. 46, 2003, pages 2774 - 2789
   AHREN ET AL., J CLIN ENDOCRINOL METAB, vol. 89, 2004, pages 2078 - 2084
   VILLHAUER ET AL., J MED CHEM, vol. 45, 2002, pages 2362 - 2365
   AHREN ET AL., DIABETES CARE, vol. 25, 2002, pages 869 - 875
   CALDWELL ET AL., BIOORG MED CHEM LETT, vol. 14, 2004, pages 1265 - 1268
   EDMONDSON ET AL., BIOORG MED CHEM, vol. 14, 2004, pages 5151 - 5155
   ABE ET AL., J NAT PROD, vol. 67, 2004, pages 999 - 1004
   CORBETT JJSAVINO PJTHOMPSON HSKANSU TSCHATZ NJORR LS ET AL.: "Visual-Loss in Pseudo-Tumor Cerebri - Follow-Up of 57 Patients from 5 to 41 Years and A Profile of 14 Patients with Permanent Severe Visual-Loss", ARCHIVES OF NEUROLOGY, vol. 39, no. 8, 1982, pages 461 - 74
   WORLD HEALTH ORGANIZATION, GLOBAL DATABASE ON BODY MASS INDEX, 2013
   SINCLAIR AJBALL AKBURDON MACLARKE CESTEWART PMCUMOW SJ ET AL.: "Exploring the pathogenesis of IIH: An inflammatory perspective", JOURNAL OF NEUROIMMUNOLOGY, vol. 201, 2008, pages 212 - 20, XP025495597, DOI: 10.1016/j.jneuroim.2008.06.029

DOI:   http://dx.doi.org/10.1016/j.jneuroim.2008.06.029
   LUECK CMCLLWAINE G: "Interventions for idiopathic intracranial hypertension", COCHRANE DATABASE OF SYSTEMATIC REVIEWS, no. 3, 2005
   BALL AHOWMAN A: "A randomised controlled trial of treatment for idiopathic intracranial hypertension", JOURNAL OF NEUROLOGY, 2010, pages 1 - 8
   CELEBISOY NGOKCAY FSIRIN HAKYUREKLI O: "Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study", ACTA NEUROLOGICA SCANDINAVICA, vol. 116, no. 5, 2007, pages 322 - 7
   CURRY WTBUTLER WEBARKER FG: "Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States", NEUROSURGERY, vol. 57, no. 1, 1988, pages 97 - 107
   SINCLAIR AJKURUVATH SSEN DNIGHTINGALE PGBURDON MAFLINT G: "Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review", CEPHALALGIA, vol. 31, no. 16, 2011, pages 1627 - 33
   ASTRUP AROSSNER SVAN GOAL LRISSANEN ANISKANEN LAL HAKIM M ET AL.: "Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study", LANCET, vol. 374, no. 9701, 2009, pages 1606 - 16, XP026742608, DOI: 10.1016/S0140-6736(09)61375-1

DOI:   http://dx.doi.org/10.1016/S0140-6736(09)61375-1
   MURPHY VAJOHANSON CE: "Alteration of Sodium-Transport by the Choroid-Plexus with Amiloride", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 979, no. 2, 1989, pages 187 - 92, XP023575693, DOI: 10.1016/0005-2736(89)90434-3

DOI:   http://dx.doi.org/10.1016/0005-2736(89)90434-3
   AMIN MSREZA EWANG HLEENEN FH: "Sodium Transport in the Choroid Plexus and Salt-Sensitive Hypertension", HYPERTENSION, vol. 54, no. 4, 2009, pages 860 - U359
   SPEAKE TWHITWELL CKAJITA HMAJID ABROWN PD: "Mechanisms of CSF secretion by the choroid plexus", MICROSCOPY RESEARCH AND TECHNIQUE, vol. 52, no. 1, 2001, pages 49 - 59
   DAVSON HSEGAL MB: "Effects of Some Inhibitors and Accelerators of Sodium Transport on Turnover of Na-22 in Cerebrospinal Fluid and Brain", JOURNAL OF PHYSIOLOGY-LONDON, vol. 209, no. 1, 1970, pages 131
   WELCH K: "Secretion of Cerebrospinal Fluid by Choroid Plexus of Rabbit", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 205, no. 3, 1963, pages 617
   ZEUTHEN TWRIGHT EM: "Electrogenic Na+-K+ Pump in Choroid-Plexus", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 511, no. 3, 1978, pages 517 - 22, XP023509694, DOI: 10.1016/0005-2736(78)90287-0

DOI:   http://dx.doi.org/10.1016/0005-2736(78)90287-0
   CAMPBELL JEDRUCKER DJ: "Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action", CELL METABOLISM, vol. 17, no. 6, 2013, pages 819 - 37
   MUSCELLI EMARI ACASOLARO ACAMASTRA SSEGHIERI GGASTALDELLI A ET AL.: "Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients", DIABETES, vol. 57, no. 5, 2008, pages 1340 - 8
   CARR RDLARSEN MOJELIC KLINDGREN OVIKMAN JHOIST JJ ET AL.: "Secretion and Dipeptidyl Peptidase-4-Mediated Metabolism of Incretin Hormones after a Mixed Meal or Glucose Ingestion in Obese Compared to Lean, Nondiabetic Men", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 95, no. 2, 2010, pages 872 - 8
   VERDICH CTOUBRO SBUEMANN BMADSEN JLHOIST JJASTRUP A: "The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction", INTERNATIONAL JOURNAL OF OBESITY, vol. 25, no. 8, 2001, pages 1206 - 14
   ALVAREZ ERONCERO ICHOWEN JATHORENS BBLAZQUEZ E: "Expression of the glucagon-like peptide-1 receptor gene in rat brain", JOURNAL OF NEUROCHEMISTRY, vol. 66, no. 3, 1996, pages 920 - 7
   BANKS WADURING MJNIEHOFF ML: "Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 309, no. 2, 2004, pages 469 - 75, XP009058592, DOI: 10.1124/jpet.103.063222

DOI:   http://dx.doi.org/10.1124/jpet.103.063222
   LOCKIE SH: "Glucagon-Like Peptide-1 Receptor in the Brain: Role in Neuroendocrine Control of Energy Metabolism and Treatment Target for Obesity", JOURNAL OF NEUROENDOCRINOLOGY, vol. 25, no. 7, 2013, pages 597 - 604
   LARSEN PJTANGCHRISTENSEN MHOIST JJORSKOV C: "Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem", NEUROSCIENCE, vol. 77, no. 1, 1997, pages 257 - 70
   GUTZWILLER JPTSCHOPP SBOCK AZEHNDER CEHUBER ARKREYENBUEHL M ET AL.: "Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 89, no. 6, 2004, pages 3055 - 61
   GUTZWILLER JPHRUZ PHUBER ARHAMEL CZEHNDER CDREWE J ET AL.: "Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans", DIGESTION, vol. 73, no. 2-3, 2006, pages 142 - 50
   TANGCHRISTENSEN MLARSEN PJGOKE RFINKJENSEN AJESSOP DSMOLLER M ET AL.: "Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats", AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, vol. 271, no. 4, 1996, pages R848 - R856, XP000973083
   VON WEBSKY KREICHETZEDER CHOCHER B: "Physiology and pathophysiology of incretins in the kidney", CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, vol. 23, no. 1, 2014, pages 54 - 60
   WEI YMOJSOV S: "Tissue-Specific Expression of the Human Receptor for Glucagon-Like Peptide-I - Brain, Heart and Pancreatic Forms Have the Same Deduced AminoAcid-Sequences", FEBS LETTERS, vol. 358, no. 3, 1995, pages 219 - 24
   GALLWITZ BWITT MFOLSCH URCREUTZFELDT WSCHMIDT WE: "Binding-Specificity and Signal-Transduction of Receptors for Glucagon-Like Peptide-1(7-36)Amide and Gastric-Inhibitory Polypeptide on Rinm5F Insulinoma Cells", JOURNAL OF MOLECULAR ENDOCRINOLOGY, vol. 10, no. 3, 1993, pages 259 - 68
   CARRARO-LACROIX LRMALNIC GGIRARDI ACC: "Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells", AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, vol. 297, no. 6, 2009, pages F1647 - F1655
   CRAJOINAS ROORICCHIO FTPESSOA TDPACHECO BPLESSA LMMALNIC G ET AL.: "Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1", AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, vol. 301, no. 2, 2011, pages F355 - F363
   EDWARDS LJSHARRACK BISMAIL ATENCH CRGRAN BDHUNGANA S ET AL.: "Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension", AM J CLIN EXP IMMUNOL, vol. 2, no. 3, 2013, pages 234 - 44
   STEFANOVIC VARDAILLOU NVLAHOVIC PPLACIER SRONCO PARDAILLOU R: "Interferon-Gamma Induces Dipeptidylpeptidase-lv Expression in Human Glomerular Epithelial-Cells", IMMUNOLOGY, vol. 80, no. 3, 1993, pages 465 - 70
   SCHREGEL KWUERFEL EGARTEISER PGEMEINHARDT IPROZOROVSKI TAKTAS O ET AL.: "Demyelination reduces brain parenchymal stiffness quantified in vivo by magnetic resonance elastography", PROC NATL ACAD SCI U S A, vol. 109, no. 17, 24 April 2012 (2012-04-24), pages 6650 - 5
   ALPERIN NRANGANATHAN SBAGCI AADAMS DERTL-WAGNER BSARAF-LAVI E ET AL.: "MRI Evidence of Impaired CSF Homeostasis in Obesity-Associated Idiopathic Intracranial Hypertension", AMERICAN JOURNAL OF NEURORADIOLOGY, vol. 34, no. 1, 2013, pages 29 - 34
   FREIMANN FBSTREITBERGER KJKLATT DLIN KMCLAUGHLIN JBRAUN J ET AL.: "Alteration of brain viscoelasticity after shunt treatment in normal pressure hydrocephalus", NEURORADIOLOGY, vol. 54, no. 3, March 2012 (2012-03-01), pages 189 - 96
   STREITBERGER KJWIENER EHOFFMANN JFREIMANN FBKLATT DBRAUN J ET AL.: "In vivo viscoelastic properties of the brain in normal pressure hydrocephalus", NMR BIOMED, vol. 24, no. 4, May 2011 (2011-05-01), pages 385 - 92
   NAKAZATO: "Development of the novel delivery system of GLP-1 administration for the treatment of diabetes mellitus", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 69, no. 5, 2011, pages 918 - 922
   BAEHR, REICHEL ET AL.: "Choroid plexus epithelial monolayers - a cell culture model from porcine brain", CEREBROSPINAL FLUID RES, vol. 3, no. 13, 2006, pages 1 - 14
   GATH UHAKVOORT AWEGENER JDECKER SGALLA HJ: "Porcine choroid plexus cells in culture: expression of polarized phenotype, maintenance of barrier properties and apical secretion of CSF-components", EUR J CELL BIOL., vol. 74, no. 1, September 1997 (1997-09-01), pages 68 - 78
   ULDALL MJUHLER MSKJOLDING ADKRUUSE CJANSEN-OLESEN IJENSEN R: "A novel method for long-term monitoring of intracranial pressure in rats", J NEUROSCI METHODS, vol. 227, April 2014 (2014-04-01), pages 1 - 9, XP028841451, DOI: 10.1016/j.jneumeth.2014.01.036

DOI:   http://dx.doi.org/10.1016/j.jneumeth.2014.01.036
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.